Loading company
Just reported
Q3 2026 results
From Lantheus's results release of November 5, 2026; its quarterly report has since been filed.
Revenue
Actual
$389.9M
+1.5% y/y
+0.4% q/qGuided
—
No guide given
EPS, GAAP
Actual
$0.33
-20% y/y
-70% q/qGuided
—
No guide given
Operating income, GAAP
Actual
$32.2M
-26% y/y
-68% q/qGuided
—
No guide given
Operating income, adjusted: $153.2M
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Lantheus is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited$33.9BA
NBIXNeurocrine Biosciences, Inc.$17.2BA+
ELANElanco Animal Health Incorporated$13.3BA
KNSAKiniksa Pharmaceuticals International, plc$8.2BA+
LQDALiquidia Corporation$5.2BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now A
Built from Lantheus Holdings, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
